Navigation Links
Candidate vaccine to reduce hepatitis C viral load.

Hepatitis C virus is the leading cause of death and liver transplant in the western world. This disease is also very common that it is incidence is five times more when compared to HIV/ AIDS. // Hence researchers at the University of Saskatchewan's Vaccine and Infectious Disease Organization (VIDO) have developed a vaccine candidate to treat hepatitis C infection.

This vaccine technique is very effective in the treatment of Hepatitis C (HCV) infection. It reduced the load of the carrier virus in the body of the mice tremendously in the order of 100000 times when compared to the control. The Canadian Institutes of Health Research (CIHR) and the Canadian Network for Vaccines and Immunotherapeutics (CANVAC) funded the research.

The researchers mainly made use of the dendritic cells to fight against the Hepatitis C virus. Dendritic cells play an important role in activation of the immune system. The vaccine significantly reduced the amount of viral protein in the body. This help us to later develop treatments which will pave way to help the patients suffering from liver disease caused by the virus.

People (20%) who have the disease remove the virus without any major problem. When the disease becomes chronic then the immune system finds it difficult to remove the viral load from the body. But studies reveal that in patients suffering from chronic hepatitis there is alteration in the function of the dendritic cells.

Hence these vaccines were created which could signal the dendritic cell and help in the proper activation of the immune system. Then the patient is in a position to control from the body.

The designing of a vaccine is very time consuming and troublesome because the virus always keeps mutating. A patient suffering from the disease may harbor with many different types of strains. Hence the VIDO came up with a vaccine that has a broad range of action and is effective against all strains.


Page: 1

Related medicine news :

1. New Test Identifies Candidates For Cardiac Defibrillator
2. HIV-Positive Woman To Be Congress Candidate In Assam
3. Reservation For SC/ST Candidates Under 50% All India Quota
4. New hope for cancer victims – will vaccine cure the deadly bug
5. New vaccine helps allergy and asthma patients
6. Man against HIV – new vaccine ready for human trials
7. New vaccine helps allergy and asthma patients
8. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
9. HIV did not arise from polio vaccine
10. Double impact vaccine
11. High Demand for a child vaccine
Post Your Comments:

(Date:11/25/2015)... MN (PRWEB) , ... November 25, 2015 , ... Finnleo, ... through Christmas Eve on several models of traditional and far-infrared saunas. , ... Nordic Spruce is the most traditional Finnish sauna wood, and Finnleo uses only European ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director at ... hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for safety ... fuller hair, without the need for surgery, prescription pills, or topical foams. , ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, ... Two Organizations, One Beat ” campaign. The partnership between the two groups began in ... in MAP International’s cause. , MAP International was founded in 1954 and is an ...
(Date:11/25/2015)... ... 2015 , ... Dental professionals who would like to become more proficient on ... Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held on ... co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to ...
(Date:11/25/2015)... IL (PRWEB) , ... November 25, 2015 , ... The ... announce a recent successful appellate decision obtained by Attorneys Francisco J. Botto and Alex ... Adcock v. Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: ... and Rugen Therapeutics, a start-up  biotechnology company focused ... CNS disorders and funded by the F-Prime Biomedical ... entered into an exclusive collaboration to support the ... Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... TEL AVIV, Israel , November 25, 2015 /PRNewswire/ ... firms (the "New Investors"), pursuant to which BioLight and ... in BioLight,s IOPtima Ltd. subsidiary ("IOPtima") via a private ... global commercialization of its innovative IOPtimate™ system used in ... a regulatory approval pathway process for the IOPtimate™ system ...
Breaking Medicine Technology: